Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance

References

• US NIH Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents – May 4, 2006 [online]. Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 14 August 2006]
   Google Scholar
• Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005;338:182–99
   PubMed Web of Science ®Google Scholar
• Cheung PK, Wynhoven B, Harrigan PR. 2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004;6: 107–16
   Google Scholar
• Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005;21:343–57
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Moretti F, Torti C, et al. HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens. J Clin Lab Anal 2005;19: 26–9
   Google Scholar
• Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6,000 samples. AIDS 2000;14:1203–10
   PubMed Web of Science ®Google Scholar
• Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958–66
   PubMed Web of Science ®Google Scholar
• Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006;166:521–8
   PubMed Web of Science ®Google Scholar
• Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487–94
   PubMed Web of Science ®Google Scholar
• Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393–401
   PubMed Web of Science ®Google Scholar
• King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005;191: 2046–52
   Google Scholar
• Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112–18
   PubMed Web of Science ®Google Scholar
• Ammassari A, Murri R, Pezzotti P, et al.; AdICONA Study Group. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445–9
   Google Scholar
• Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9:695–702
   PubMed Web of Science ®Google Scholar
• Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 2004;30:1–10
   PubMed Web of Science ®Google Scholar
• Girardi E. Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl 2003;35:17–20
   Google Scholar
• Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69:5087–94
   PubMed Web of Science ®Google Scholar
• Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483–9
   PubMed Web of Science ®Google Scholar
• Lal RB, Chakrabarti S, Yang C. Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy and vaccine development. Indian J Med Res 2005;121: 287–314
   Google Scholar
• Drosopoulos WC, Rezende LF, Wainberg MA, et al. Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? J Mol Med 1998;76:604–12
   PubMed Web of Science ®Google Scholar
• Keulen W, Nijhuis M, Schuurman R, et al. Reverse transcriptase fidelity and HIV-1 variation. Science 1997;275:229–31
   PubMed Web of Science ®Google Scholar
• Spira S, Wainberg MA, Loemba H, et al. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003;51:229–40
   PubMed Web of Science ®Google Scholar
• Back NK, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040–9
   PubMed Web of Science ®Google Scholar
• Berkhout B. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 1999;6:298–305
   PubMed Web of Science ®Google Scholar
• Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol 2000;49:41–66
   Google Scholar
• Chen R, Quinones-Mateu ME, Mansky LM. Drug resistance, virus fitness and HIV-1 mutagenesis. Curr Pharm Des 2004;10:4065–70
   PubMed Web of Science ®Google Scholar
• Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco, California, USA. Abstract 52
   Google Scholar
• Ruane P, Luber A, Akil B, et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 582
   Google Scholar
• Gallant JE, Gerondelis PZ, Wainberg MA, et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003;8:489–506
   PubMed Web of Science ®Google Scholar
• Condra JH. Resistance to HIV protease inhibitors. Haemophilia 1998;4:610–5
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769–802
   PubMed Web of Science ®Google Scholar
• Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998;72: 7632–7
   Google Scholar
• Erickson JW. The not-so-great escape. Nat Struct Biol 1995;2:523–9
   PubMedGoogle Scholar
• Gulnik SV, Suvorov LI, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282–7
   PubMed Web of Science ®Google Scholar
• King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol 2004;11:1333–8
   PubMed Web of Science ®Google Scholar
• Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem 1996;271: 31957–63
   Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338: 853–60
   PubMed Web of Science ®Google Scholar
• De Clercq E. New developments in anti-HIV chemotherapy. Curr Med Chem 2001;8:1543–72
   PubMed Web of Science ®Google Scholar
• Cohen C, Steinhart CR, Ward DJ, et al. 48-week durable efficacy and safety results of TMC125 in HIV patients with NNRTI and PI resistance-study TMC125-C223. 12th Annual Conference of the British HIV Association (BHIVA); March 29–April 1, 2006; Brighton, UK. Abstract 2
   Google Scholar
• de Bethune M-P, Andries K, Azijn H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profile. 12th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, 22–25 February 2005. Abstract S56
   Google Scholar
• Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998;42:3218–24
   PubMed Web of Science ®Google Scholar
• Poppe SM, Slade DE, Chong KT, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997;41:1058–63
   PubMed Web of Science ®Google Scholar
• Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000;14:1943–8
   PubMed Web of Science ®Google Scholar
• Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000;44:2093–9
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039–46
   PubMed Web of Science ®Google Scholar
• Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 2004;18: 775–9
   PubMed Web of Science ®Google Scholar
• Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003;47:3123–9
   PubMed Web of Science ®Google Scholar
• Surleraux DL, Tahri A, Verschueren WG, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005;48:1813–22
   PubMed Web of Science ®Google Scholar
• King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004;78:12012–21
   PubMed Web of Science ®Google Scholar
• Dierynck I, Keuleers IM, De Wit M, et al. Kinetic characterization of the potent activity of TMC114 on wild-type HIV-1 protease. 14th International HIV Drug Resistance Workshop; June 7–11, 2005; Quebec City, Quebec, Canada. Abstract 64
   Google Scholar
• Shuman CF, Hamalainen MD, Danielson UH. Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J Mol Recognit 2004;17: 106–19
   Google Scholar
• Muzammil S, Kang LW, Armstrong AA, et al. Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations associated with drug resistance. 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24–27, 2005; Rio de Janeiro, Brazil. Abstract WePp0103
   Google Scholar
• Ghosh AK, Kincaid JF, Cho W, et al. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg Med Chem Lett 1998;8:687–90
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Kato R, Kavlick MF, et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol 2002;76:1349–58
   PubMed Web of Science ®Google Scholar
• Ohtaka H, Velazquez-Campoy A, Xie D, et al. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci 2002;11:1908–6
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Leshchenko S, Noetzel M. Stereoselective photo-chemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5h)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J Org Chem 2004;69: 7822–9
   Google Scholar
• De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314–21
   PubMed Web of Science ®Google Scholar
• Staes M, Van Craenenbroeck E, Vermeiren H, et al. Analyses of susceptibility and cross-resistance between TMC114 and other protease inhibitors among > 56,000 routine samples, using linear regression model-based fold change predictions. Antivir Ther 2006;11:S33, Abstract 28
   Google Scholar
• De Meyer S, Cao-Van K, Lathouwers E, et al. Phenotypic and genotypic profiling of TMC114, lopinavir and tipranavir against PI-resistant HIV-1 clinical isolates. 4th European HIV Drug Resistance Workshop; March 29–31, 2006; Monte Carlo, Cote d’Azur, Monaco. Abstract 42
   Google Scholar
• De Meyer S, Azjin H, Fransen E, et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Antivir Ther 2006:11:S24, Abstract 19
   Google Scholar
• Katlama C, Carvalho MTM, Cooper D, et al. TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: Week 24 primary efficacy analysis of POWER 1 (TMC114-c213). 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24–27, 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102
   Google Scholar
• Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wk primary analysis of the POWER 2 study (C202). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16–19, 2005; Washington DC, USA. Abstract H–413
   Google Scholar
• De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Antivir Ther 2006:11:S83, Abstract 73
   Google Scholar